OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
🇺🇸United States
A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug-drug Interaction
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2022-02-18
- Target Recruit Count
- 56
- Registration Number
- NCT02174822
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Phase 3
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney DiseaseChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2018-08-08
- Target Recruit Count
- 1370
- Registration Number
- NCT02160145
Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
Phase 4
Completed
- Conditions
- Device Latency
- Interventions
- Drug: PlaceboCombination Product: Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2021-10-26
- Target Recruit Count
- 30
- Registration Number
- NCT02091882
A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2021-11-23
- Target Recruit Count
- 121
- Registration Number
- NCT02068352
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2015-12-30
- Target Recruit Count
- 97
- Registration Number
- NCT02054702
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
Completed
- Conditions
- Bipolar 1 DisorderNervous System DisordersSchizophreniaMental Disorder
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2014-01-31
- Target Recruit Count
- 47
- Registration Number
- NCT02050854
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2020-04-17
- Target Recruit Count
- 3
- Registration Number
- NCT02020278
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-03-29
- Target Recruit Count
- 37
- Registration Number
- NCT02013531
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2018-09-26
- Target Recruit Count
- 9
- Registration Number
- NCT02012959
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2016-03-29
- Target Recruit Count
- 48
- Registration Number
- NCT02013609
© Copyright 2025. All Rights Reserved by MedPath